Company profile

Servier

Diversified pharma

Privately held: no public share price · France

Assets

(4 total)
4Total Assets
0Approved
1Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Ivosidenib
Phase 3
Mutant IDH1Small molecule
Acute Myeloid Leukemia
S230815
Phase 2
KCNT1 mRNARNA / oligonucleotide
Epilepsy
S241656
Phase 2
RAFSmall molecule
Non-Small Cell Lung CancerAcute Myeloid Leukemia
S243249
Phase 2
Menin-KMT2A protein-protein interaction
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.